NICE says inhaled insulin "too expensive" for UK, Pfizer appeals to health professionals
The UK advisory body charged with recommending effec-tive clinical treatment and controlling costs, the National Institute for Health and Clinical Excellence (NICE), has issued a recommendation that global giant Pfizer's Exubera (insulin human [rDNA origin]) should not be given to National Health Service patients, on the grounds that the product is not cost-effective for the treatment of diabetes.
Furious Pfizer issues "call for action"
The news was received with ill-disguised fury by Olivier Brandicourt, Pfizer UK's managing director, who, in a statement, issued "a call for action for everyone with a stake in making sure innovative new medicines that imp-rove quality of life get to patients who need them most."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze